287 related articles for article (PubMed ID: 24810250)
1. The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series.
Bergman J; Pashinian A; Weizman A; Poyurovsky M
Int Clin Psychopharmacol; 2014 Sep; 29(5):263-5. PubMed ID: 24810250
[TBL] [Abstract][Full Text] [Related]
2. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
4. Citalopram in refractory obsessive-compulsive disorder: an open study.
Marazziti D; Dell'Osso L; Gemignani A; Ciapparelli A; Presta S; Nasso ED; Pfanner C; Cassano GB
Int Clin Psychopharmacol; 2001 Jul; 16(4):215-9. PubMed ID: 11459335
[TBL] [Abstract][Full Text] [Related]
5. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
[TBL] [Abstract][Full Text] [Related]
6. Escitalopram in the treatment of obsessive-compulsive disorder.
Zohar J
Expert Rev Neurother; 2008 Mar; 8(3):339-49. PubMed ID: 18345966
[TBL] [Abstract][Full Text] [Related]
7. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.
Stein DJ; Andersen EW; Overo KF
Braz J Psychiatry; 2007 Dec; 29(4):303-7. PubMed ID: 18200396
[TBL] [Abstract][Full Text] [Related]
8. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
[TBL] [Abstract][Full Text] [Related]
9. Obsessive-compulsive disorder: an open-label pilot trial of escitalopram.
Galvão-de Almeida A; Quarantini LC; Góis CR; Santos-Jesus R; Miranda-Scippa AM; de Oliveira IR; da Silva Prado H; Leckman JF; Rosário MC
CNS Spectr; 2007 Jul; 12(7):519-24. PubMed ID: 17603402
[TBL] [Abstract][Full Text] [Related]
10. High-dose escitalopram treatment in patients with obsessive-compulsive disorder: a naturalistic case series.
Shim GS; Kang DH; Kwon JS
J Clin Psychopharmacol; 2008 Feb; 28(1):108-10. PubMed ID: 18204356
[No Abstract] [Full Text] [Related]
11. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Pallanti S; Quercioli L; Koran LM
J Clin Psychiatry; 2002 Sep; 63(9):796-801. PubMed ID: 12363120
[TBL] [Abstract][Full Text] [Related]
12. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases.
Thomsen PH
J Child Adolesc Psychopharmacol; 1997; 7(3):157-66. PubMed ID: 9466233
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of high-dose escitalopram in the treatment of patients suffering from schizophrenia with comorbid obsessive-compulsive disorder: an open-label study.
Rubin-Kahana DS; Shelef A; Weizman A; Gothelf D; Timinski I; Spivak B; Stryjer R
Int Clin Psychopharmacol; 2019 Jul; 34(4):179-183. PubMed ID: 31058717
[TBL] [Abstract][Full Text] [Related]
14. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
[TBL] [Abstract][Full Text] [Related]
15. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Pallanti S; Quercioli L; Bruscoli M
J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram for antipsychotic nonresponsive visual hallucinosis: eight patients suffering from Charles Bonnet syndrome.
Bergman Y; Barak Y
Int Psychogeriatr; 2013 Sep; 25(9):1433-6. PubMed ID: 23676430
[TBL] [Abstract][Full Text] [Related]
17. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.
Koponen H; Lepola U; Leinonen E; Jokinen R; Penttinen J; Turtonen J
Acta Psychiatr Scand; 1997 Nov; 96(5):343-6. PubMed ID: 9395151
[TBL] [Abstract][Full Text] [Related]
18. Citalopram for treatment-resistant obsessive-compulsive disorder.
Pallanti S; Quercioli L; Paiva RS; Koran LM
Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Mundo E; Bianchi L; Bellodi L
J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
[TBL] [Abstract][Full Text] [Related]
20. Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial.
Mowla A; Modarresi F; Dastgheib SA
Asian J Psychiatr; 2018 Dec; 38():92-95. PubMed ID: 29158148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
